Taking on analysts’ expectations and winning: Gossamer Bio Inc. (GOSS)

Gossamer Bio Inc. (NASDAQ: GOSS) stock fell -1.26% on Friday to $11.77 against a previous-day closing price of $11.92. With 1.25 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.90 whereas the lowest price it dropped to was $11.13. The 52-week range on GOSS shows that it touched its highest point at $14.30 and its lowest point at $5.64 during that stretch. It currently has a 1-year price target of $16.10. Beta for the stock currently stands at 1.02.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GOSS was down-trending over the past week, with a drop of -2.08%, but this was up by 57.35% over a month. Three-month performance surged to 64.85% while six-month performance rose 24.03%. The stock gained 49.56% in the past year, while it has gained 4.07% so far this year. A look at the trailing 12-month EPS for GOSS yields -3.11 with Next year EPS estimates of -2.41. For the next quarter, that number is -0.70. This implies an EPS growth rate of 12.00% for this year and 14.60% for next year.

Float and Shares Shorts:

At present, 75.89 million GOSS shares are outstanding with a float of 68.97 million shares on hand for trading. On Apr 28, 2022, short shares totaled 10.44 million, which was 13.54% higher than short shares on Mar 30, 2022. In addition to Mr. Faheem Hasnain as the firm’s Co-Founder, CEO, Pres & Chairman, Mr. Bryan Giraudo serves as its COO & CFO.

Institutional Ownership:

Through their ownership of 89.34% of GOSS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 42.13% of GOSS, in contrast to 28.09% held by mutual funds. Shares owned by individuals account for 20.64%. As the largest shareholder in GOSS with 9.62% of the stake, HHLR Advisors Ltd. holds 7,420,974 shares worth 7,420,974. A second-largest stockholder of GOSS, The Vanguard Group, Inc., holds 5,578,840 shares, controlling over 7.23% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in GOSS, holding 4,594,187 shares or 5.96% stake. With a 3.50% stake in GOSS, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,699,666 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Small C, which owns about 3.24% of GOSS stock, is the second-largest Mutual Fund holder. It holds 2,500,000 shares valued at 20.93 million. Vanguard Total Stock Market Index holds 2.46% of the stake in GOSS, owning 1,898,257 shares worth 15.89 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GOSS since 9 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 2 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GOSS analysts setting a high price target of $21.00 and a low target of $12.00, the average target price over the next 12 months is $15.78. Based on these targets, GOSS could surge 78.42% to reach the target high and rise by 1.95% to reach the target low. Reaching the average price target will result in a growth of 34.07% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GOSS will report FY 2022 earnings on 03/24/2023. Analysts have provided yearly estimates in a range of -$1.98 being high and -$3.10 being low. For GOSS, this leads to a yearly average estimate of -$2.66. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Gossamer Bio Inc. surprised analysts by $0.01 when it reported -$0.76 EPS against a consensus estimate of -$0.77. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.44 and the low estimate is -$0.79. The average estimate for the next quarter is thus -$0.68.

Summary of Insider Activity:

Insiders traded GOSS stock several times over the past three months with 0 Buys and 3 Sells. In these transactions, 0 shares were bought while 11,848 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 0 while 77,017 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *